Developed by Johnson & Johnson, Topamax, also known as topiramate, is a drug used to treat epilepsy and seizures. During clinical trials, though, researchers discovered the drug's ability to control weight gain. In fact, users lost up to twelve percent of their body weight after taking Topamax for two years.
Johnson & Johnson immediately began clinical trials of Topamax for weight loss but recently discontinued the program after users suffered negative side effects. According to a company spokesperson, patients experienced tingling sensations, fatigue, sleeplessness, and memory problems. Researchers involved in the obesity trials remained positive, though, saying they would begin working on a new version of the drug soon and resume clinical trials within a year.
Topamax made headlines recently when Johnson & Johnson issued a warning to health officials that at least twenty-three Topamax patients developed glaucoma while taking the drug.